A recent study found the drug combination lenalidomide + rituximab is a durable, effective and safe alternative to the standard regimen combining rituximab and chemotherapy.
The treatment is approved for patients who have a moderate to high risk of recurrence, following nephrectomy or nephrectomy accompanied by surgical resection of metastatic lesions.
The global study estimates the effect of alcohol consumption on cancers worldwide, suggesting 4% of newly diagnosed cases in 2020 may have been associated with drinking alcohol.